Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer Authors: Catharina J. P. Op ‘t Hoog, Niven Mehra, Benthe van der Weij, Erik Olofsen, Diederik M. Somford, Inge M. van Oort, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter Published: 2026 ABSTRACT Background and ObjectivePain management in patients with prostate cancer receiving enzalutamide is challenging owing to its high potential for drug–drug interactions. Morphine is generally preferred because of its favorable metabolic profile, but the effect of enzalutamide on the pharmacokinetics of morphine is unclear. The objective of this study was to assess whether a drug–drug interaction exists between enzalutamide and morphine in patients with prostate cancer.MethodsIn a multicenter two-arm parallel study, 24 men with prostate cancer received morphine with enzalutamide (n = 12) and without enzalutamide (n = 12). Plasma concentrations of morphine and its active metabolite morphine-6-glucuronide were measured. Pharmacokinetic parameters were calculated using a non-compartmental analysis. Geometric mean ratios (GMR) of the area under the plasma concentration–time curves were calculated. No clinically relevant interaction was defined if 90% of the confidence interval (CI) of the GMR of morphine was within the range of 0.5–2.0.ResultsMorphine exposure was similar between both groups, with the 90% CI falling within the range of 0.5–2.0 (GMR 1.01; 90% CI 0.77–1.31). The exposure of morphine-6-glucuronide was increased with enzalutamide (GMR 1.77; 90% CI 1.43–2.17).ConclusionsThe exposure of morphine was unaffected by enzalutamide, while morphine-6-glucuronide exposure was increased. Because of the inconclusive potency of morphine-6-glucuronide and its uncertain ability to cross the blood–brain barrier, the increase is likely of modest clinical significance. Therefore, morphine and enzalutamide can be safely combined when starting at a low dose and titrated based on efficacy and tolerability.Clinical Trial RegistrationNCT05339672. Key Summary Points Enzalutamide has a high potential for drug–drug interactions, including uridine 5′-diphospho-glucuronosyltransferases.The opioid morphine is generally preferred in combination with enzalutamide because of its favorable metabolic profile, but the effect of enzalutamide on morphine is unclear.The average exposure of morphine was similar with and without enzalutamide.Despite the increase of its active metabolite, it is expected that enzalutamide and morphine can safely be co-administered. Enzalutamide has a high potential for drug–drug interactions, including uridine 5′-diphospho-glucuronosyltransferases.The opioid morphine is generally preferred in combination with enzalutamide because of its favorable metabolic profile, but the effect of enzalutamide on morphine is unclear.The average exposure of morphine was similar with and without enzalutamide.Despite the increase of its active metabolite, it is expected that enzalutamide and morphine can safely be co-administered. Introduction Enzalutamide is a potent androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway [1]. Enzalutamide has shown efficacy in several stages of prostate cancer and has improved progression-free survival and overall survival [1–6]. As enzalutamide has a high drug–drug interaction (DDI) potential, the use of enzalutamide induces clinical challenges [7–9]. Specifically, prostate cancer is known to metastasize to the bones, which can cause severe pain limiting quality of life [10, 11]. Consequently, many patients receiving enzalutamide require analgesics for pain management, typically opioids [12, 13]. Both enzalutamide and its active metabolite, N-desmethyl-enzalutamide (NDME), are strong cytochrome P450 (CYP) 3A4 inducers and moderate CYP2C19 and CYP2C9 inducers [8]. As most opioids are predominantly metabolized by CYP3A4, treatment can be challenging in combination with enzalutamide. Concomitant treatment with enzalutamide showed a clinically relevant effect on both fentanyl and oxycodone pharmacokinetics, through CYP3A4 induction [14, 15]. Fentanyl and oxycodone are therefore not considered suitable options for pain management in patients with prostate cancer receiving enzalutamide. Morphine is often recommended for patients treated with enzalutamide as the preferred opioid in clinical practice because its metabolism is largely independent of CYP enzymes. Instead, morphine is primarily metabolized by uridine 5′-diphospho-glucuronosyltransferase (UGT) enzymes, primarily UGT2B7 with a minor contribution of UGT1A1, to form morphine-3-glucuronide, an inactive metabolite that compromised approximately 50% of the formed metabolites, and morphine-6-glucuronide (M6G), an active metabolite that compromised approximately 10% of the formed metabolites of morphine [16–21]. Furthermore, morphine is metabolized by CYP3A4 into the minor metabolite normorphine, which accounts for less than 5% of the formed metabolites [17, 22]. It is suggested in some studies that M6G has an equivalent analgesic potency to morphine, but with a more favorable adverse-event profile, specifically less nausea, vomiting, and respiratory depression [16, 19]. However, specific data on its relative analgesic effect and safety profile compared to morphine remain inconclusive [18, 19, 23, 24]. It is hypothesized that enzalutamide induces CYP3A enzymes through activation of the nuclear pregnane X receptor, which regulates the DNA transcription of several enzymes and transporters and is also suggested to be linked to the induction of some UGT enzymes [25]. In contrast, in vitro data indicated that enzalutamide inhibits UGT1A1 and UGT2B7 [26, 27]. Consequently, the net clinical effect of enzalutamide on UGT enzymes remains unclear. Because of the frequent need to use opioids for pain management in this patient population and the uncertain effect of enzalutamide on UGT, it remains unclear if morphine pharmacokinetics are affected by enzalutamide and therefore if the use of morphine in combination with enzalutamide should be advised for these patients. Therefore, the aim of this study was to investigate the effect of enzalutamide on morphine pharmacokinetics in patients with prostate cancer in order to confirm safe use and better inform clinical practice. Method Study Design A prospective, multicenter, open-label, two-arm parallel study has been performed in men with prostate cancer receiving morphine. The study consisted of two arms: patients using enzalutamide and patients not using enzalutamide both treated with morphine. Patients were enrolled in three hospitals in the Netherlands (Canisius Wilhelmina Hospital, Nijmegen; Franciscus Gasthuis & Vlietland, Rotterdam; Radboud University Medical Centre, Nijmegen). Eligible patients were diagnosed with prostate cancer and received morphine. Participants were either on treatment with twice-daily morphine extended release (XR), morphine immediate release (IR), or were opioid naïve and willing to receive a single dose of morphine IR. In the enzalutamide arm, patients were either treated or started treatment with enzalutamide according to standard patient care. The dose of enzalutamide was according to the drug label and the physician’s discretion. Patients were included if they had a life expectancy of more than 3 months and a stable renal function with an estimated glomerular filtration rate of ≥ 50 mL/min. Patients who used co-medication or other anti-cancer drugs possibly affecting the pharmacokinetics of morphine or enzalutamide were excluded. Furthermore, patients with a contraindication for morphine were also excluded. The study (NCT05339672) was approved by the local medical research ethics committee and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent prior to participating in the study. Pharmacokinetic (PK) and Safety Assessment Patients were scheduled for pharmacokinetic (PK) assessment at the hospital. Patients receiving enzalutamide and/or morphine XR were scheduled when steady-state concentrations were reached (after 4 weeks and 2 days, respectively). Patients documented their medication intake and adverse events in a diary until the PK assessment day. Additionally, adverse events were evaluated on the PK assessment day. For patients receiving morphine XR, blood samples were collected at predose, and at ½, 1, 1½, 2, 3, 4, 8, and 12 h after morphine administration. For patients receiving single-dose morphine IR, blood samples were collected at ½, 1, 1½, 2, 3, 4, 6, and 8 h after administration. Additionally, in all patients receiving enzalutamide treatment, a predose sample was taken to measure plasma trough concentrations (Ctrough) of enzalutamide and its metabolite NDME. Morphine and M6G plasma concentrations were measured at the pharmacy laboratory of the Amsterdam University Medical Center (Amsterdam, the Netherlands) using a validated liquid chromatography tandem mass spectrometry with electrospray ionization method. The calibration curves of morphine and M6G cover the range of 0.5–500 µg/L. The intra-day precision was ≤ 7.2% and the inter-day precision was ≤ 11.4%. Accuracy ranged from 95.9 to 108.6%. Method validation was performed in accordance with the “Guideline on bioanalytical method validation” of the European Medicines Agency [28]. Trough plasma concentrations of enzalutamide and its metabolite NDME were measured at the pharmacy laboratory of the Radboud University Medical Center (Nijmegen, the Netherlands) using a validated liquid chromatography tandem mass spectrometry method [29]. Endpoints The primary endpoint of this study was to determine the change in morphine exposure, measured as the area under the plasma concentration–time curve (AUC), with and without enzalutamide. For morphine IR, the AUC was calculated up to the last measured point and then extrapolated to infinity, whereas for morphine XR this was calculated over one dosing interval of 12 h. The AUC from time zero to infinity following a single dose of morphine IR 10 mg is equal to the AUC from time zero to 12 h at steady state over one dosing interval for morphine XR 10 mg [30, 31]. The morphine AUCs with and without enzalutamide were compared according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guideline on bioequivalence studies [32]. Secondary endpoints were the change in M6G exposure (AUC), morphine and M6G maximum plasma concentrations (Cmax), and morphine and M6G trough concentrations (Ctrough) with and without enzalutamide. Because drug release differs between the morphine formulations, Cmax and Ctrough from the IR and XR formulations were analyzed separately and only compared the Cmax for the IR formulation between both groups. Enzalutamide and NDME concentrations were measured to confirm patients had normal enzalutamide plasma concentrations. The safety of concomitant use of enzalutamide and morphine was evaluated using Common Terminology Criteria for Adverse Events Version 5.0 [33]. PK and Statistical Analysis Descriptive statistics were used to present patient characteristics. Continuous variables were expressed as medians with their ranges, while categorical variables were presented as counts and percentages. Differences between groups were tested with an independent samples t-test for continuous normally distributed data, a Mann–Whitney U test for skewed continuous variables, and a Fisher’s exact test or chi-squared test for categorical data. Analyses were performed using RStudio (Version 2024.04.2). A p-value of < 0.05 was considered statistically significant. A non-compartmental PK analysis was conducted using Phoenix WinNonlin (Version 8.4) to determine the PK parameters (AUC, Cmax, and Ctrough) of morphine and M6G in patients with and without enzalutamide. The PK parameters measured were AUC and Cmax for morphine IR, and AUC, Cmax, and Ctrough for morphine XR. The AUCs were calculated using the log-linear trapezoidal rule. The geometric mean of the PK parameters of morphine and M6G were calculated and compared between the patients treated with and without enzalutamide. A DDI was considered non-clinically relevant if the 90% confidence interval (CI) of the geometric mean ratio (GMR) of the morphine AUC fell within the range of 0.5–2.0. The conventional range for bioequivalence according to the guidelines of the US Food and Drug Administration and the European Medicines Agency is 0.8–1.25 but may be wider if substantiated [34, 35]. In this study, a wider acceptance range was selected because no clear exposure–response relationship has been established for morphine, and both intrasubject and intersubject variability are relatively large, with an intersubject variability of 54% of the morphine AUC [36, 37]. Additionally, in clinical practice, morphine dosing is not individualized on plasma concentrations but titrated based on clinical response, which includes analgesic effects and tolerability. Therefore, a 25% difference in morphine exposure is not expected to require dose adjustments. However, a two-fold difference is expected to necessitate dose adjustments, and thus the predefined range was set at 0.5–2.0. It was calculated that a total sample size of 24 patients, with 12 patients with and 12 patients without enzalutamide, was required to demonstrate a non-clinically relevant interaction, based on a significance level of 0.05, a power of 0.8 and a standard deviation of the intersubject variation (CV%) of 54% [38]. Results In total, 26 patients were eligible for inclusion in the study from February 2023 to July 2025. Two patients were excluded: one patient who experienced a serious adverse event and subsequently withdrew from the study, and one patient who withdrew informed consent after inclusion. A total of 24 patients were included in the PK analysis, of which 12 patients received the combination of morphine with enzalutamide and 12 patients received morphine without enzalutamide. In total, two patients received morphine XR 10 mg and 22 patients received single-dose morphine IR 10 mg. The patient characteristics are summarized in Table 1. No statistical differences between groups were found. Table 1Patient characteristicsWith enzalutamide (n = 12)Without enzalutamide (n = 12)Demographicsp-valueAge, years75 (68–79)68 (55–83)0.156Height, cm180 (171–190)179 (167–189)0.377Weight, kg87 (75–130)89 (69–105)0.844BMI, kg/m227 (23–36)29 (24–31)0.745Ethnicity1.000AsianCaucasian12 (100%)1 (8%)11 (92%)ECOG Performance Status0.6760–110 (75%)12 (100%)21 (8%)–Unknown1 (8%)–Tumor characteristics and treatmentSetting1.000CRPC8 (67%)7 (58%)HSPC4 (33%)5 (42%)Gleason score at diagnosis0.365Low grade (3–6)1 (8%)–Intermediate grade (7)2 (17%)5 (42%)High grade (8–10)7 (58%)7 (58%)Unknown2 (17%)–Prior local treatmentRadiotherapy8 (67%)9 (92%)0.315Orchidectomy1 (8%)–1.000Radical prostatectomy4 (33%)2 (17%)0.637Prior systemic therapyAbiraterone3 (25%)5 (42%)0.665Abiraterone + olaparib1 (8%)–1.000Alpelisib1 (8%)1 (8%)1.000Chemotherapy8 (67%)5 (42%)0.413Enzalutamide–3 (25%)N/AImmunotherapy1 (8%)3 (25%)0.584Current systemic therapyAbiraterone–1 (8%)N/AADT11 (92%)9 (75%)0.584Olaparib monotherapy–1 (8%)N/AEnzalutamide12 (100%)–N/ANo therapy–1 (8%)N/AMorphine formulation and doseIR 10 mg10 (83%)0 (0%)XR 10 mg2 (17%)12 (100%)Enzalutamide dose (mg)120 mg2 (17%)–160 mg10 (83%)–Laboratory measurementsHemoglobin, mmol/L8.2 (5.0–9.2)8.0 (6.6–9 .5)0.895Creatinine, µmol/L79 (50–124)83 (38–114)0.932eGFR (mL/min/1.73 m2)85 (50–>90)87 (51–>90)0.589ALT, U/L14 (7–17)25 (7–58)0.067AST, U/L22 (17–25)26 (22–42)0.006LDH, U/L215 (172–360)215 (178–266)1.000GammaGT, U/L16 (11–26)27 (14–32)0.097Alkaline phosphatase, U/L79 (43–166)83 (40–333)0.859Total bilirubin, µmol/L6 (4–11)6 (3–13)0.664Albumin, g/L36 (31–44)34 (30–38)0.088PSA, µg/L2.1 (0.1–120)0.5 (0.1–53)0.907Testosterone, nmol/L0.5 (<0.4–1)0.4 (<0.4–14.0)0.807Data are presented as presented as median (minimum–maximum) or N (%)ADT androgen deprivation therapy, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, CRPC castration-resistant prostate cancer, ECOG Eastern Cooperative Oncology Group, eGFR estimated glomerular filtration rate, GammaGT gamma-glutamyltransferase, HSPC hormone-sensitive prostate cancer, IR immediate release, LDH lactate dehydrogenase, N/A not available, PSA prostate-specific antigen, XR extended release Table 1Patient characteristicsWith enzalutamide (n = 12)Without enzalutamide (n = 12)Demographicsp-valueAge, years75 (68–79)68 (55–83)0.156Height, cm180 (171–190)179 (167–189)0.377Weight, kg87 (75–130)89 (69–105)0.844BMI, kg/m227 (23–36)29 (24–31)0.745Ethnicity1.000AsianCaucasian12 (100%)1 (8%)11 (92%)ECOG Performance Status0.6760–110 (75%)12 (100%)21 (8%)–Unknown1 (8%)–Tumor characteristics and treatmentSetting1.000CRPC8 (67%)7 (58%)HSPC4 (33%)5 (42%)Gleason score at diagnosis0.365Low grade (3–6)1 (8%)–Intermediate grade (7)2 (17%)5 (42%)High grade (8–10)7 (58%)7 (58%)Unknown2 (17%)–Prior local treatmentRadiotherapy8 (67%)9 (92%)0.315Orchidectomy1 (8%)–1.000Radical prostatectomy4 (33%)2 (17%)0.637Prior systemic therapyAbiraterone3 (25%)5 (42%)0.665Abiraterone + olaparib1 (8%)–1.000Alpelisib1 (8%)1 (8%)1.000Chemotherapy8 (67%)5 (42%)0.413Enzalutamide–3 (25%)N/AImmunotherapy1 (8%)3 (25%)0.584Current systemic therapyAbiraterone–1 (8%)N/AADT11 (92%)9 (75%)0.584Olaparib monotherapy–1 (8%)N/AEnzalutamide12 (100%)–N/ANo therapy–1 (8%)N/AMorphine formulation and doseIR 10 mg10 (83%)0 (0%)XR 10 mg2 (17%)12 (100%)Enzalutamide dose (mg)120 mg2 (17%)–160 mg10 (83%)–Laboratory measurementsHemoglobin, mmol/L8.2 (5.0–9.2)8.0 (6.6–9 .5)0.895Creatinine, µmol/L79 (50–124)83 (38–114)0.932eGFR (mL/min/1.73 m2)85 (50–>90)87 (51–>90)0.589ALT, U/L14 (7–17)25 (7–58)0.067AST, U/L22 (17–25)26 (22–42)0.006LDH, U/L215 (172–360)215 (178–266)1.000GammaGT, U/L16 (11–26)27 (14–32)0.097Alkaline phosphatase, U/L79 (43–166)83 (40–333)0.859Total bilirubin, µmol/L6 (4–11)6 (3–13)0.664Albumin, g/L36 (31–44)34 (30–38)0.088PSA, µg/L2.1 (0.1–120)0.5 (0.1–53)0.907Testosterone, nmol/L0.5 (<0.4–1)0.4 (<0.4–14.0)0.807Data are presented as presented as median (minimum–maximum) or N (%)ADT androgen deprivation therapy, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, CRPC castration-resistant prostate cancer, ECOG Eastern Cooperative Oncology Group, eGFR estimated glomerular filtration rate, GammaGT gamma-glutamyltransferase, HSPC hormone-sensitive prostate cancer, IR immediate release, LDH lactate dehydrogenase, N/A not available, PSA prostate-specific antigen, XR extended release Patient characteristics Asian Caucasian 1 (8%) 11 (92%) Data are presented as presented as median (minimum–maximum) or N (%) ADT androgen deprivation therapy, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, CRPC castration-resistant prostate cancer, ECOG Eastern Cooperative Oncology Group, eGFR estimated glomerular filtration rate, GammaGT gamma-glutamyltransferase, HSPC hormone-sensitive prostate cancer, IR immediate release, LDH lactate dehydrogenase, N/A not available, PSA prostate-specific antigen, XR extended release PK Analysis The mean plasma concentration–time curves of morphine were similar with and without enzalutamide (Fig. 1). The geometric mean of the morphine AUC was similar in the patients treated with enzalutamide (24.3 µg*h/L) compared to the patients without enzalutamide (24.4 µg*h/L), resulting in a GMR of 1.01. The 90% CI of the GMR for morphine AUC was 0.77–1.31, which fell within the predefined range of 0.5–2.0 of a non-clinically relevant interaction. The Cmax values of morphine IR with and without enzalutamide were 6.3 µg/L and 7.2 µg/L, respectively, with a GMR of 0.87 (90% CI 0.65–1.15). The PK parameters of morphine are presented in Table 2. The intersubject variability in morphine exposure in patients treated with and without enzalutamide was 39% and 33%, respectively.Fig. 1Morphine mean plasma concentration–time curve of morphine immediate release with and without enzalutamide. Error bars represent standard deviations. h hoursTable 2Pharmacokinetic parameters of morphine and M6G in patients with and without enzalutamideWith enzalutamide (CV%) [95% CI] N = 12Without enzalutamide (CV%) [95% CI] N = 12GMR [90% CI]MorphineAUCa (h*µg/L)24.3 (41%) [19–31]24.4 (36%) [19–30]1.01 [0.77–1.31]Cmaxb (µg/L) (IR)6.3 (47%) [4.6–8.7]7.2 (41%) [5.6–9.2]0.87 [0.65–1.15]Cmaxc (µg/L) (XR)6.0 (28%) [0.5–73]––Ctroughc (µg/L)1.8 (85%)––M6GAUCa (h*µg/L)315 (33%) [257–386]178 (27%) [150–212]1.77 [1.43–2.17]Cmaxb (µg/L) (IR)47 (28%) [38–57]34 (23%) [30–40]1.40 [1.18–1.67]Cmaxc (µg/L) (XR)56 (13%) [17–180]––Ctroughc (µg/L)27 (82%)––Data are represented in geometric mean (CV%)AUC area under the plasma concentration–time curve, AUC0–inf area under the plasma concentration–time curve from time zero to infinity, AUC0–12h area under the plasma concentration–time curve from time zero to 12 h, CI confidence interval, Cmax maximum plasma concentration, Ctrough trough plasma concentration, CV coefficient of variation, GMR geometric mean ratio, IR immediate release, M6G Morphine-6-glucuronide, XR extended releaseaGeometric mean includes the AUC0–inf of the IR formulation and the AUC0–12h of the morphine XR formulationbN = 10cN = 2 Morphine mean plasma concentration–time curve of morphine immediate release with and without enzalutamide. Error bars represent standard deviations. h hours Table 2Pharmacokinetic parameters of morphine and M6G in patients with and without enzalutamideWith enzalutamide (CV%) [95% CI] N = 12Without enzalutamide (CV%) [95% CI] N = 12GMR [90% CI]MorphineAUCa (h*µg/L)24.3 (41%) [19–31]24.4 (36%) [19–30]1.01 [0.77–1.31]Cmaxb (µg/L) (IR)6.3 (47%) [4.6–8.7]7.2 (41%) [5.6–9.2]0.87 [0.65–1.15]Cmaxc (µg/L) (XR)6.0 (28%) [0.5–73]––Ctroughc (µg/L)1.8 (85%)––M6GAUCa (h*µg/L)315 (33%) [257–386]178 (27%) [150–212]1.77 [1.43–2.17]Cmaxb (µg/L) (IR)47 (28%) [38–57]34 (23%) [30–40]1.40 [1.18–1.67]Cmaxc (µg/L) (XR)56 (13%) [17–180]––Ctroughc (µg/L)27 (82%)––Data are represented in geometric mean (CV%)AUC area under the plasma concentration–time curve, AUC0–inf area under the plasma concentration–time curve from time zero to infinity, AUC0–12h area under the plasma concentration–time curve from time zero to 12 h, CI confidence interval, Cmax maximum plasma concentration, Ctrough trough plasma concentration, CV coefficient of variation, GMR geometric mean ratio, IR immediate release, M6G Morphine-6-glucuronide, XR extended releaseaGeometric mean includes the AUC0–inf of the IR formulation and the AUC0–12h of the morphine XR formulationbN = 10cN = 2 Pharmacokinetic parameters of morphine and M6G in patients with and without enzalutamide Data are represented in geometric mean (CV%) AUC area under the plasma concentration–time curve, AUC0–inf area under the plasma concentration–time curve from time zero to infinity, AUC0–12h area under the plasma concentration–time curve from time zero to 12 h, CI confidence interval, Cmax maximum plasma concentration, Ctrough trough plasma concentration, CV coefficient of variation, GMR geometric mean ratio, IR immediate release, M6G Morphine-6-glucuronide, XR extended release aGeometric mean includes the AUC0–inf of the IR formulation and the AUC0–12h of the morphine XR formulation bN = 10 cN = 2 The mean plasma concentration–time curve of M6G was increased for patients using enzalutamide, compared with patients without enzalutamide (Fig. 2). The geometric mean AUC for M6G in patients treated with enzalutamide was 315 µg*h/L, compared with 178 µg*h/L for patients without enzalutamide, with a GMR of 1.77 (90% CI 1.43–2.17). The Cmax values of M6G with morphine IR with and without enzalutamide were 47 µg/L and 34 µg/L, respectively (GMR 1.40; 90% CI 1.18–1.67). The metabolic ratio of M6G/morphine was 13 in the enzalutamide group compared with 7 in the group without enzalutamide. The PK parameters of M6G are presented in Table 2.Fig. 2Morphine-6-glucuronide mean plasma concentration–time curve of morphine immediate release with and without enzalutamide. Error bars represent standard deviations. h hours Morphine-6-glucuronide mean plasma concentration–time curve of morphine immediate release with and without enzalutamide. Error bars represent standard deviations. h hours The median sum Ctrough plasma concentration of enzalutamide and NDME was 18.4 mg/L (range 14.0–23.0 mg/L). No concentration-dependent effect of the sum concentrations of enzalutamide and NDME on morphine and M6G exposure was found. Safety One serious adverse event of grade 3 related to morphine XR was reported in a patient without enzalutamide, involving hospitalization because of malaise associated with nausea and vomiting. This patient subsequently withdrew from the study before the PK assessment and was replaced by another patient. All other adverse events were grade 1 or 2. Reported enzalutamide-related adverse events were fatigue (n = 2), hot flashes (n = 2), muscle pain (n = 1), memory impairment (n = 1), and restless legs (n = 1). Reported morphine-related adverse events were nausea (n = 1 with enzalutamide and n = 1 without enzalutamide), fatigue (n = 2 without enzalutamide), and constipation (n = 1 without enzalutamide). Discussion This study investigated the potential DDI between morphine and enzalutamide. Co-administration of enzalutamide did not alter the morphine exposure. In contrast, exposure of the active metabolite M6G increased by 77%. These findings indicate enzalutamide did not affect the metabolism and elimination of morphine but did affect M6G disposition. This is the first study investigating the potential DDI between morphine and enzalutamide. Enzalutamide is a strong CYP3A4 inducer and moderate CYP2C19 and CYP2C9 inducer [8]. Its CYP induction profile is similar to rifampicin [39]. Previous research on the DDI between morphine and rifampicin demonstrated a decrease in the exposure of morphine and M6G in combination with rifampicin of 27% and 19%, respectively [40]. This decrease was hypothesized to be driven by induction of P-glycoprotein (P-gp) in the intestine, kidneys, and bile, which could lead to an increased excretion of morphine and its glucuronides and that could hamper its analgesic effects [40]. In contrast, our study showed that morphine exposure remained similar with and without enzalutamide, while the exposure to M6G increased in combination with enzalutamide. These differences suggest that although enzalutamide and rifampicin share similar CYP3A4 inducing potential, their effect on P-gp is not expected to be comparable. The absence of a change in morphine exposure could be explained by the fact that enzalutamide is a mild P-gp inhibitor. In contrast, rifampicin is considered a potent P-gp inducer, and a similar induction could theoretically be anticipated for enzalutamide through pregnane X receptor activation [25, 41]. However, in earlier studies enzalutamide only showed a small increase in plasma exposure of the P-gp probe drug digoxin (33%) [9]. This was attributed to local inhibitory effects of enzalutamide on intestinal P-gp, while also inducing systemic P-gp through pregnane X receptor activation. This results in a net effect on P-gp, which has led to classification of enzalutamide as a mild P-gp inhibitor [9, 41]. In this study, the exposure of M6G was significantly increased in combination with enzalutamide by 77%. As morphine is primarily metabolized into active and inactive metabolites by several UGTs, it could be suggested that the increase in metabolite exposure is attributed to UGT induction, while this is contradicted by the unchanged morphine exposure [16]. Because other morphine metabolites, such as morphine-3-glucuronide and normorphine, were not included in our analysis, the exact influence of enzalutamide on other metabolic pathways involved in morphine metabolism remains unclear. The increase in M6G exposure could more likely be explained by a decrease in metabolite clearance by the kidneys [17, 42]. In earlier research, renal clearance of M6G exceeded creatinine clearance, suggesting a major role for active transport in the elimination process [17]. A possible explanation for the observed increase in M6G exposure is that enzalutamide inhibits active renal transport. Yet, it is unclear what the role of specific transporters such as P-gp, organic anion transporters, and organic cation transporters is on M6G clearance [22, 43]. In vitro data suggest that enzalutamide can interact with several of these transporters. The increase in M6G exposure might be caused by decreased active elimination through systemic P-gp inhibition by enzalutamide in the kidneys [26]. Although enzalutamide increased the exposure of M6G, this effect is unlikely to be clinically relevant. Several studies have described analgesic activity of M6G, but its potency remains inconclusive [18, 19, 23, 24]. It is suggested that although M6G has a high affinity for the mu-receptor responsible for the analgesic effect, crossing of the blood–brain barrier is thought to be limited [16, 44–46]. This is supported by clinical studies in which M6G has been studied as an alternative to morphine, showing insufficient pain relief [24]. Morphine-6-glucuronide was therefore not pursued for market authorization. The contribution of M6G on pain control is therefore thought to be modest. Despite the 77% increase in M6G during co-administration with enzalutamide in our study, M6G plasma concentration remained substantially lower than the M6G concentrations needed in the clinical studies of M6G to achieve equipotent efficacy as morphine, indicating that its overall contribution to the analgesic effect and toxicity of morphine remains limited [24, 44, 47]. Nevertheless, in patients receiving long-term and high-dose morphine, M6G accumulation could be more pronounced. A similar pattern is observed in patients with renal failure, where M6G exposure is increased relative to individuals with normal kidney function, while morphine exposure remains largely unchanged [42, 48, 49]. In patient with renal impairment, it is advised to start with a low dose of morphine and increase the dose based on efficacy and tolerability. By analogy, a similar caution measure could be suggested for patients starting morphine while treated with enzalutamide. In our study, all patients had enzalutamide and NDME sum concentrations similar to previous PK studies [8, 50]. Pharmacogenetic genotypes were not measured, nor were available for the patients at study inclusion, while polymorphisms could have influenced the intersubject variability of morphine and M6G. However, the morphine exposure and variability observed in our study was consistent with previously reported findings at similar doses [51–53]. Therefore, we conclude that pharmacogenetic polymorphisms, if present, did not affect our PK outcome and the patients in our study are considered representative for the general patient population. Conclusions The exposure of morphine was similar with and without enzalutamide, while M6G exposure was increased in combination with enzalutamide. Although the ability of M6G to cross the blood–brain barrier is unclear and the literature on its analgesic potency is inconclusive, the relative contribution of M6G to overall morphine potency remains low, and the clinical relevance of this increase in M6G is likely modest. While the combination of morphine and enzalutamide is considered safe, it is recommended to start morphine at a low dose and titrate based on efficacy and tolerability.